Alcamena
Alcamena is dedicated to developing the most advanced protein optimization and development platform using proprietary directed evolution techniques. Their approach is versatile, fast, and capable of producing proteins with high binding affinities and tissue permeability, validated through independent academic collaborations. They offer services in protein and peptide library generation, screening, and development to meet specific project goals.
Industries
Nr. of Employees
small (1-50)
Alcamena
Patents
Compositions and methods for derepressing RE1 silencing transcription factor target genes
US-12180255-B2
View Details
Compositions and methods for derepressing RE1 silencing transcription factor target genes
US-12180255-B2
View DetailsProducts
High-affinity orally bioavailable cyclic peptidomimetic inhibitor (example candidate)
A small (approx. 3 kDa) cyclic peptidomimetic that demonstrated low-picomolar binding to a phosphatase target and low-nanomolar cellular activity; designed for oral bioavailability and cell permeability.
ASCT-1003
A discovery and preclinical stage drug targeting the β-TrCP:REST pathway for neurodegenerative conditions and cancers.
ASCT-1
A pre-IND stage permeability enhancer.
ASCT-83
Clinical stage first-in-class drug that antagonizes CTDSP1 and REST, targeting the undruggable REST:CTDSP1 protein-protein interaction.
ASCT-1124
IL-6 antagonist peptide therapeutic currently in co-development pipeline.
ASCT-1201
TNF-alpha antagonist peptide therapeutic currently in co-development pipeline.
High-affinity orally bioavailable cyclic peptidomimetic inhibitor (example candidate)
A small (approx. 3 kDa) cyclic peptidomimetic that demonstrated low-picomolar binding to a phosphatase target and low-nanomolar cellular activity; designed for oral bioavailability and cell permeability.
ASCT-1003
A discovery and preclinical stage drug targeting the β-TrCP:REST pathway for neurodegenerative conditions and cancers.
ASCT-1
A pre-IND stage permeability enhancer.
ASCT-83
Clinical stage first-in-class drug that antagonizes CTDSP1 and REST, targeting the undruggable REST:CTDSP1 protein-protein interaction.
ASCT-1124
IL-6 antagonist peptide therapeutic currently in co-development pipeline.
ASCT-1201
TNF-alpha antagonist peptide therapeutic currently in co-development pipeline.
Services
End-to-end discovery service using directed evolution and high-diversity libraries to identify and optimize peptides/proteins for binding affinity, enzymatic activity, stability and tissue permeability.
Design and build custom peptide libraries (site-saturation, combinatorial, insertion-deletion, homology-based, synthetic, de novo) and develop bespoke display or enzymatic screens.
Coordination and execution support for IND-enabling activities including enzymatic/cellular assays, transgenic mouse efficacy studies, toxicology, safety pharmacology and regulatory study planning.
Assignment of a dedicated project director to design experimental strategy, manage execution, and provide client communications throughout the project lifecycle.
End-to-end discovery service using directed evolution and high-diversity libraries to identify and optimize peptides/proteins for binding affinity, enzymatic activity, stability and tissue permeability.
Design and build custom peptide libraries (site-saturation, combinatorial, insertion-deletion, homology-based, synthetic, de novo) and develop bespoke display or enzymatic screens.
Coordination and execution support for IND-enabling activities including enzymatic/cellular assays, transgenic mouse efficacy studies, toxicology, safety pharmacology and regulatory study planning.
Assignment of a dedicated project director to design experimental strategy, manage execution, and provide client communications throughout the project lifecycle.
Expertise Areas
- Directed evolution and affinity maturation
- Peptidomimetic and CPP design
- High-diversity peptide library construction
- Display-based high-throughput screening
Key Technologies
- Directed evolution
- mRNA display
- Phage display
- Bacterial display